OTC FILING WATCH · LIVEOfficial-source OTC filing intelligence
ISSUER DOSSIER · CIK 0001615219

Salarius Pharmaceuticals, Inc. (SLRX)

Issuer profile3 captured filing nodes

Business context

Official SEC registration filing — S-1/A. Read the linked SEC filing for business, risk factors and offering details.

First captured2025-07-31
Latest filingS-1/A · 2025-09-23
Registration path0 initial filings · 3 amendments

What to watch next

Compare the next amendment against the current filing, then monitor for EFFECT or 424B. Material offering terms can change between amendments.

Latest captured filing: S-1/A · 2025-09-23 · 311 days ago.

ISSUER CHANGE LEDGER

Newly detected public-record events

Events first captured by this monitoring workflow for this CIK. Open the source and the filing brief before making any legal, diligence or transaction conclusion.

  1. S-1/ASalarius Pharmaceuticals, Inc. (SLRX)Official source →
  2. S-1/ASalarius Pharmaceuticals, Inc. (SLRX)Official source →
  3. S-1/ASalarius Pharmaceuticals, Inc. (SLRX)Official source →
SHELL DILIGENCE CHAIN · PUBLIC-RECORD VIEW

Evidence chain for this issuer

Built from 3 captured SEC filing nodes, from 2025-07-31 through 2025-09-23. It shows what has been observed in the record and what still needs independent verification.

  1. Identity anchorCIK 0001615219 · issuer name carried from the SEC filing history
  2. Registration entryNo initial S-1 / F-1 is in the captured record
  3. Amendment trail3 amendments captured
  4. Effectiveness / prospectusNo EFFECT or 424B is in the captured record
  5. Ongoing record watchLatest captured form: S-1/A on 2025-09-23
OBSERVEDIssuer identity

CIK and issuer name are linked to the captured SEC filing sequence.

OPEN CHECKRegistration sequence

Not present in the currently captured SEC record. This is not a negative finding.

OBSERVEDAmendment history

3 amendments captured for comparison.

OPEN CHECKPublic completion evidence

Not present in the currently captured SEC record. This is not a negative finding.

Verification queue

  • Confirm current legal entity, officers, directors and control from the controlling filing and corporate records.
  • Review capitalization, transfer-agent information and any beneficial-ownership questions through the client’s qualified advisers.
  • Compare material business, financing and risk disclosure changes in the official source documents.

Source boundary

Forms captured: S-1/A. This is an evidence map, not a safety rating, shell determination, legal opinion, valuation or transaction recommendation. Absence from a captured source is never proof that a fact does not exist.

Open Evidence Snapshot →
Generate automated SEC filing brief
PUBLIC-RECORD DILIGENCE

Need a documented diligence trail?

Use this issuer dossier as the starting evidence layer. A defined scope can package the official filing history, public company actions and questions for your independently retained advisers to review.

Official filing timeline

  1. S-1/A · official filing

    Salarius Pharmaceuticals, Inc. (SLRX)

  2. S-1/A · official filing

    Salarius Pharmaceuticals, Inc. (SLRX)

  3. S-1/A · official filing

    Salarius Pharmaceuticals, Inc. (SLRX)

Open latest official filing →